Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
The user shared progress pictures after four months of using finasteride, minoxidil, a dermaroller, and biotin for hair loss. They discussed their treatment regimen and results.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
The user is seeing progress in hair regrowth using a combination of 8% minoxidil, 0.25% dutasteride, and 0.01% tretinoin. The conversation includes comments on the effectiveness and application of these treatments.
Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.
A user who had FUT surgery for 2877 grafts with Dr Jerry Wong of Hasson & Wong that resulted in low growth and an abnormally wide scar, suggesting negligence by the doctor and possibly illegal behaviour by an unqualified technician. The post sparked discussion about seeking legal action, as well as criticism of the clinic's high cost.
The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.
User found 15% procyanidin B2 supplement and asks if it's legit. Recommended dosage is 400-600mg daily, similar to study, and user wonders if it's effective for hair loss.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The user is seeking advice on improving their hair loss treatment regimen, considering changes to their topical solution, and is curious about others' daily routines and recommendations for medications and supplements. They are contemplating switching Tretinoin for Tazarotene, Latanoprost for Bimatoprost, and possibly adding Alfatradiol, Topical Melatonin, or a topical androgen receptor antagonist.
The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.
The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.
The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.
The conversation discusses hair thinning and potential treatments, focusing on vitamin D supplements and their effects. Other suggestions include zinc, a high-protein diet, and coconut oil for hair health.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The conversation discusses hair loss treatments for a 30-year-old female, comparing red light therapy with minoxidil and finasteride. Concerns about hormonal impact and potential pregnancy are raised, with suggestions to consider spironolactone and microneedling, while emphasizing the importance of consulting a dermatologist.
The conversation is a satirical discussion about a baby with hair loss using adult hair loss treatments like finasteride, minoxidil, and ketoconazole, as well as dermarolling, scalp massages, and plans for PRP sessions. Suggestions include various other treatments and humorous advice, reflecting the satire of the situation.
The importance of lighting when taking progress pictures and discussing hair growth, as dramatic changes can be seen even without real improvements. The users also discussed methods such as Fin min and dermarolling for treating hair loss.
The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.
Topical melatonin was found to significantly increase hair density and decrease scalp conditions like seborrheic dermatitis. The user is considering using it alongside finasteride and oral minoxidil for treating hair loss and scalp health.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The user is experiencing severe hair loss despite using treatments like DUT, oral minoxidil, ketoconazole, RU58841, and vitamins. They plan to buzz their hair due to the ongoing hair fall and its impact on their mental health and self-esteem.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
The user is experiencing thinning at the temporal points and has been using minoxidil, dermarolling, and a mixture of natural oils to improve hair growth. They are considering finasteride as a potential treatment based on shared information.
The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.